Premium
Pharmacotherapy in Cancer Patients With HIV/AIDS
Author(s) -
Beumer J H,
Venkataramanan R,
Rudek M A
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2014.10
Subject(s) - medicine , life expectancy , human immunodeficiency virus (hiv) , pharmacotherapy , antiretroviral therapy , drug , cancer , antiretroviral agents , intensive care medicine , cancer therapy , oncology , immunology , pharmacology , viral load , population , environmental health
Antiretroviral therapy (ART) has significantly reduced morbidity and increased life expectancy of individuals infected with human immunodeficiency virus (HIV). Consequently, non–acquired immunodeficiency syndrome (AIDS)‐defining malignancies are increasing in frequency, which necessitates the concurrent use of antineoplastics and ART. Although drug interactions are a major concern when combining these agents, there is currently limited guidance on dose adjustments required to maintain safe and efficacious drug exposure. Clinical Pharmacology & Therapeutics (2014); 95 4, 370–372. doi: 10.1038/clpt.2014.10